CYDYCorporate•globenewswire•
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Sentiment:Negative (0)
Summary
(CYDY) VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by globenewswire